Olga  Aprelikova, Ph.D.
Olga Aprelikova, Ph.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 37, Room 1042
Bethesda, MD 20892
301-435-5774

Currently Dr. Aprelikova studies chromosomal and molecular aberrations selected by tumors driven by well-defined oncogenes, with focus on Myc-induced mammary carcinomas. The major interest of the study is in Myc cooperation with epigenetic modifiers of histone and non-histone proteins involved in transformation of primary epithelial cell and established tumors. Another Dr. Aprelikova’s interests are focused on changes in tumor microenvironment that stimulates primary tumor progression and/or distant metastasis. She identified several microRNAs that are deregulated in cancer-associated fibroblasts and ascertained the effect of those microRNAs and their target genes on tumor growth and motility.

Areas of Expertise
tumor microenvironment, hypoxia, microRNA, breast cancer, Myc oncogene
Selected Publications
  1. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, Risinger JI, Barrett JC, Niederhuber J.
    Cancer Res.. 69: 616-24, 2009. [ Journal Article ]
  2. Aprelikova O.
    Cell Cycle. 8: 2868, 2009. [ Journal Article ]
  3. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J.
    Oncogene. 32: 3246-53, 2013. [ Journal Article ]
  4. Aprelikova O, Green JE.
    Cancer Immunol. Immunother.. 61: 231-7, 2012. [ Journal Article ]
  5. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J.
    Cell Cycle. 9: 4387-98, 2010. [ Journal Article ]

Dr. Aprelikova received both her bachelor and master's degree in biochemistry from Moscow University and her Ph.D. from Institute of Cytology in St. Petersburg. She continued her postdoctoral training in the Friedrich Miescher Institute in Basel, Switzerland, in the Laboratory of Dr. Joseph Jiricny, where she focused on the repair of spontaneous DNA lesions, and then in the University of Helsinki in the Laboratory of Dr. Kari Alitalo, where she identified, cloned and characterized the novel VEGF receptor, FLT4. In 1993 she joined the Laboratory of Dr. Edison Liu in the UNC at Chapel Hill, where she studied the biological function of BRCA1. She started working at NCI in 1997 and continued research in breast cancer, and later, in tumor hypoxia.

Summary

Currently Dr. Aprelikova studies chromosomal and molecular aberrations selected by tumors driven by well-defined oncogenes, with focus on Myc-induced mammary carcinomas. The major interest of the study is in Myc cooperation with epigenetic modifiers of histone and non-histone proteins involved in transformation of primary epithelial cell and established tumors. Another Dr. Aprelikova’s interests are focused on changes in tumor microenvironment that stimulates primary tumor progression and/or distant metastasis. She identified several microRNAs that are deregulated in cancer-associated fibroblasts and ascertained the effect of those microRNAs and their target genes on tumor growth and motility.

Areas of Expertise
tumor microenvironment, hypoxia, microRNA, breast cancer, Myc oncogene

Publications

Selected Publications
  1. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, Risinger JI, Barrett JC, Niederhuber J.
    Cancer Res.. 69: 616-24, 2009. [ Journal Article ]
  2. Aprelikova O.
    Cell Cycle. 8: 2868, 2009. [ Journal Article ]
  3. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J.
    Oncogene. 32: 3246-53, 2013. [ Journal Article ]
  4. Aprelikova O, Green JE.
    Cancer Immunol. Immunother.. 61: 231-7, 2012. [ Journal Article ]
  5. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J.
    Cell Cycle. 9: 4387-98, 2010. [ Journal Article ]

Biography

Dr. Aprelikova received both her bachelor and master's degree in biochemistry from Moscow University and her Ph.D. from Institute of Cytology in St. Petersburg. She continued her postdoctoral training in the Friedrich Miescher Institute in Basel, Switzerland, in the Laboratory of Dr. Joseph Jiricny, where she focused on the repair of spontaneous DNA lesions, and then in the University of Helsinki in the Laboratory of Dr. Kari Alitalo, where she identified, cloned and characterized the novel VEGF receptor, FLT4. In 1993 she joined the Laboratory of Dr. Edison Liu in the UNC at Chapel Hill, where she studied the biological function of BRCA1. She started working at NCI in 1997 and continued research in breast cancer, and later, in tumor hypoxia.